NewAmsterdam Pharma (NAMS)
21.58
+0.32 (1.51%)
Upcoming Events
Latest Headlines
NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $42 at RBC Capital
October 5, 2026 7:02 AM - StreetInsider
Form 4 NewAmsterdam Pharma Co For: Sep 30 Filed by: Kastelein Johannes Jacob Pieter
October 2, 2026 4:31 PM - SEC Filing
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026 4:01 PM - StreetInsider
NewAmsterdam Pharma begins Phase 2b trial of obicetrapib in Alzheimer's
September 29, 2026 8:00 AM - StreetInsider
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29, 2026 8:00 AM - StreetInsider
Stifel on NewAmsterdam Pharma Co NV (NAMS): 'the risk/reward is very compelling'
September 21, 2026 10:13 AM - StreetInsider
EU approves NewAmsterdam and Menarini's obicetrapib drugs
September 21, 2026 9:00 AM - StreetInsider
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026 9:00 AM - StreetInsider
NewAmsterdam Pharma CEO buys 10,000 shares at $22.65
September 15, 2026 4:37 PM - StreetInsider
Form 4 NewAmsterdam Pharma Co For: Sep 14 Filed by: Davidson Michael H.
September 15, 2026 4:30 PM - SEC Filing
NewAmsterdam Pharma Co NV (NAMS) Reiterated at Buy by Stifel
September 8, 2026 6:55 AM - StreetInsider
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026 4:01 PM - StreetInsider
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
September 2, 2026 8:00 AM - StreetInsider
NewAmsterdam Pharma (NAMS) call put ratio 1 call to 1 put on 3900 contracts
August 31, 2026 5:32 AM - StreetInsider
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
August 26, 2026 8:00 AM - StreetInsider
Form 4 NewAmsterdam Pharma Co For: Aug 24 Filed by: Kastelein Johannes Jacob Pieter
August 25, 2026 4:30 PM - SEC Filing
Form 3 NewAmsterdam Pharma Co For: Aug 10 Filed by: Gunning Robert William
August 14, 2026 4:13 PM - SEC Filing
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026 4:01 PM - StreetInsider
NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $50 at RBC Capital
August 6, 2026 6:52 AM - StreetInsider
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2026 7:00 AM - StreetInsider
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026 8:00 AM - StreetInsider
EU panel backs NewAmsterdam and Menarini cholesterol drugs
July 24, 2026 8:00 AM - StreetInsider
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co
July 24, 2026 8:00 AM - StreetInsider
Form 4 NewAmsterdam Pharma Co For: Jul 20 Filed by: Kooij Louise Frederika
July 22, 2026 4:05 PM - SEC Filing
BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform
July 20, 2026 4:36 PM - StreetInsider
Jefferies Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
July 20, 2026 11:36 AM - StreetInsider
Attovia Therapeutics names John Smither to board of directors
July 15, 2026 8:30 AM - StreetInsider
Attovia Therapeutics Appoints John W. Smither to Board of Directors
July 15, 2026 8:30 AM - Globe NewsWire
Full Article List
